Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Drug-Drug Interaction Study of Lasmiditan
Latest Information Update: 14 Jul 2020
Price :
$35 *
At a glance
- Drugs Lasmiditan (Primary)
- Indications Migraine
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 20 Jun 2020 Results presented at the 62nd Annual Scientific Meeting of the American Headache Society
- 05 Mar 2018 Status changed from recruiting to completed.
- 18 Aug 2017 Status changed from not yet recruiting to recruiting.